Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression
Liver International · 2026
DOI: 10.1111/liv.70478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Wei Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Changzhou Key Laboratory of Exosome Basics and Translational Applications, Wujin Hospital Affiliated With Jiangsu University, Changzhou, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, RNA Polymerase I, Liver Cirrhosis, Ribosomes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background & Aims Liver fibrosis significantly burdens global health, and increased protein synthesis during hepatic stellate cell (HSC) activation plays a crucial role in its progression. Ribosome is the site of protein synthesis. RNA polymerase I (Pol I) is a protein that regulates the transcription of ribosomal DNA (rDNA) genes into ribosomal RNA (rRNA) in ribosomal biogenesis. Therefore, we investigated the role and mechanism of Pol I‐regulated ribosome biogenesis in HSCs activation and liver fibrosis progression.
Methods
Initially, we assessed the expression levels of Pol I in the serum of patients diagnosed with liver fibrosis. Then, we assessed Pol I‐regulated ribosome biogenesis levels in mouse models of metabolic dysfunction‐associated steatohepatitis (MASH) and carbon tetrachloride (CCl 4 ). Finally, we employed overexpression or knockdown of the Pol I gene in LX2 cells or utilised the Pol I inhibitor CX‐5461 in vivo and in vitro, assessing the levels of ribosome biogenesis and HSCs activation.
Results
Pol I levels were elevated in the serum of patients with liver fibrosis. Additionally, Pol I‐regulated ribosome biogenesis levels were significantly increased in both MASH and CCl 4 mouse models, as well as in HSCs activated by transforming growth factor beta 1 (TGFβ1). The overexpression of Pol I was found to enhance the activation of HSCs and promote ribosome biogenesis, while the knockdown of Pol I or the inhibitor CX‐5461 inhibited these processes.
Conclusions
Pol I‐regulated ribosome biogenesis is significantly increased during HSCs activation and liver fibrosis progression. Pol I may serve as a potential target for the diagnosis and treatment of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changzhou Key Laboratory of Exosome Basics and Translational Applications, Wujin Hospital Affiliated With Jiangsu University, Changzhou, China.
- Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Changzhou, China.
- Department of Medical Technology, Suzhou Vocational Health College, Suzhou, Jiangsu, China.
- Department of Laboratory Medicine, Wujin Hospital Affiliated With Jiangsu University (Wujin Clinical College of Xuzhou Medical University), Changzhou, China.
ORCID-Profile: Fatma A Abouelnazar, Yongmin Yan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Luo, W., Yi, L., Zhang, Y., Zhou, J., Li, S., Abouelnazar, F. A., Wang, Y., & Yan, Y. (2026). Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression. Liver International. https://doi.org/10.1111/liv.70478
Vancouver
Luo W, Yi L, Zhang Y, Zhou J, Li S, Abouelnazar FA, et al. Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression. Liver International. 2026. doi:10.1111/liv.70478
BibTeX
@article{Luo2026,
author = {Luo, Wei and Yi, Lixian and Zhang, Yu and Zhou, Jing and Li, Shihui and Abouelnazar, Fatma A and Wang, Yanjin and Yan, Yongmin},
title = {Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70478}
}
EUVIMED